The Life Sciences Virtual Investor Forum, a B2i Digital Featured Conference co-hosted by Virtual Investor Conferences and Zacks Small-Cap Research, is scheduled for June 24 and 25, 2026. The event provides direct access to management teams of public life sciences companies through live presentations, real-time Q&A, and one-on-one meetings, according to a press release from B2i Digital, Inc.
The two-day lineup spans clinical-stage biotechnology, rare-disease and oncology therapeutics, molecular diagnostics, medical devices, veterinary medicine, nutrition science, and AI-powered digital health. Presenting companies as of June 17 include Protalix BioTherapeutics, CytoSorbents Corporation, Jaguar Health, and Reviva Pharmaceuticals on day one, and Prostatype Genomics, IMUNON, Envoy Medical, and aTyr Pharma on day two, among others.
B2i Digital, as the Official Marketing Partner, brings the forum into its ecosystem, anchored by a distribution and media engine that drives qualified investors to the presentations and one-on-one meetings. The company amplifies the event across its platform, putting these life sciences companies in front of a proprietary network of more than 1.7 million retail and institutional market participants. The same visibility engine has carried more than 115 investor conferences, operating under the mantra "From Marketing to Meetings."
Zacks Small-Cap Research, a preferred provider in the OTC Markets Group's Research Marketplace, prepares independent company-sponsored research and related content for distribution across investor and media channels. Its team of life sciences analysts supports the forum as co-host, adding independent research to the event.
Each company has 30 minutes for a live presentation and Q&A. One-on-one meeting requests are available through the VIC site, with replays available on B2i Digital and OTC Markets YouTube channels. Investors can request one-on-one meetings at this link.
“Life sciences investors want efficient, direct access to management teams developing the therapies and technologies that matter, and pairing that access with independent research from Zacks makes the forum more valuable on both sides,” said David Shapiro, Chief Executive Officer of B2i Digital. “Over two days, investors can meet companies across biotech, diagnostics, devices, and digital health, and reach their own conclusions.”
The forum’s importance lies in its efficiency for investors: rather than traveling to multiple conferences, they can access a curated group of innovative public companies from one platform. The inclusion of Zacks Small-Cap Research adds an independent analytical perspective, helping investors evaluate opportunities. For the companies, the event offers exposure to a broad investor base, potentially impacting their ability to raise capital or increase shareholder engagement.
Registration and company profiles are available at the Virtual Investor Conferences website. Throughout the year, Virtual Investor Conferences feature public companies from exchanges worldwide, including NYSE, Nasdaq, TSX, TSXV, CSE, ASX, LSE, and the OTC Markets. Virtual Investor Conferences is an OTC Markets Group Inc. property.
Additional details about B2i Digital and the forum can be found at B2i Digital's website.
